➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Medtronic
Moodys
Dow
Harvard Business School

Last Updated: January 27, 2021

DrugPatentWatch Database Preview

Litigation Details for Cornerstone Biopharma Inc. v. Exela Pharma Sciences LLC (D. Del. 2013)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Cornerstone Biopharma Inc. v. Exela Pharma Sciences LLC
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Cornerstone Biopharma Inc. v. Exela Pharma Sciences LLC
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Cornerstone Biopharma Inc. v. Exela Pharma Sciences LLC (D. Del. 2013)

Date Filed Document No. Description Snippet Link To Document
2013-07-24 1 Code, involving United States Patent No. 7,612,102 (“the ’102 patent”) (attached as Exhibit A hereto… § 355(b)(1), the ’102 patent and the ’291 patent (collectively, “the Patents-in-Suit”) are listed in…. This is an action for patent infringement arising under the patent laws of the United States, …hereto), and United States Patent No. 7,659,291 (“the ’291 patent”) (attached as Exhibit B hereto). …certification”) with regard to the ’102 patent and the ’291 patent (“Exela’s Notice Letter”). External link to document
2015-07-09 105 U.S. Patent Nos. 7,612,102("the'102 patent"); 7,659,290 ("the '290 patent"… ORDER CONSTRUING THE TERMS OF U.S. PATENT NOS. 7,612,102; 7,659,290; 7,659,291 and 8,455,524. Signed…CONSTRUING THE TERMS OF U.S. PATENT NOS. 7,612,102; 7,659,290; 7,659,291and8,455,5247,659,291 ("the '291 patent"); and 8,455,524 ("the '524 patent") (collectively, the… the "patents-in-suit"): 1. The term "a pre-mixed aqueous solution& External link to document
2013-08-19 20 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,612,102 B2; US 7,659,291 … 14 December 2015 1:13-cv-01275-GMS Patent None District Court, D. Delaware External link to document
2013-07-24 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,612,102 B2; US 7,659,291 … 14 December 2015 1:13-cv-01275-GMS Patent None District Court, D. Delaware External link to document
2015-02-20 53 macromolecules for pulmonary delivery. U.S. Patent No. 6,660,715; December 9, 2003. 16. Tiller, J.C.,…infringement of U.S. Patent Nos. 7,612,102 (“the ’102 patent”), 7,695,290 (“the ’290 patent”), 7,659,291 (… (“the ’291 patent”), and 8,455,524 (“the ’524 patent”) (collectively, “the patents in suit”), all of…inventor of 18 issued United States patents and of a number of foreign patents. I have given 370 invited lectures… ’291 patent, claims 1–3, 8 ’524 patent, claims 1–3, 8, 19–22 External link to document
2015-02-20 56 U.S. Patent Nos. 7,612,102 (“the ’102 Patent”), 7,659,290 (“the ’290 Patent”), 7,659,291 (“the ’291 Patent…The ’290 and ’291 Patents are divisional patents of the ’102 Patent, and the ’524 Patent is a continuation… Patent”) and 8,455,524 (“the ’524 Patent”). The patents in suit are all from the same family,2 and they… the ’102 Patent is the parent or grandparent to the other patents in suit, and the patents have the …INTRODUCTION This patent infringement action involves four patents relating to the drug product External link to document
2015-02-27 57 four patents- in-suit, U.S. Patent Nos. 7,612,102 (“the ’102 patent”), 7,659,290 (“the ’290 patent”), …7,659,291 (“the ’291 patent”), and 8,455,524 (“the ’524 patent”) (collectively, the “patents-in-suit”).1 … to the specifications of the patents-in-suit are to the ’102 patent. 4 Concentrated, injectable nicardipine…5 The patents-in-suit are all children of the application that issued as the ’102 patent. “[P]…“prior art cited in a patent or cited in the prosecution history of the patent constitutes intrinsic External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Dow
Harvard Business School
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.